Four things a generic IO framework misses
Viral shedding is a biosafety question, not a footnote
The patient can shed replicating virus after dosing — household-contact guidance and environmental precautions are part of the safety plan, not an add-on.
Injection-site reactions follow a different pattern
Local inflammatory and infectious-appearing reactions at the injection site need signal criteria that distinguish expected viral activity from a true complication.
Disseminated infection is a distinct, low-frequency risk
Immunocompromised patients or unintended spread beyond the injection site is a rare but serious risk category a standard IO safety plan doesn't name.
Combination immunotherapy compounds the read
Oncolytic viruses are frequently paired with checkpoint inhibitors — separating viral-agent effects from immune-related adverse events takes a reviewer fluent in both.
Four recurring failure points
Shedding-monitoring and household-contact protocols treated as a biosafety-committee formality instead of a core part of the clinical safety plan.
Injection-site and viral-activity signals adjudicated by a reviewer without the biosafety literacy to separate expected activity from a true complication.
Institutional biosafety committee (IBC) requirements and shedding-study design started too late to keep pace with the clinical protocol.
Sites activated without the biosafety infrastructure or IBC approval the protocol assumes is already in place.
Where the judgment sits, stage by stage
Shedding-monitoring design and injection-site signal definitions, set alongside the IBC submission.
Site readiness review — IBC approval and biosafety infrastructure confirmed before activation.
Named physician adjudicates injection-site and viral-activity signals against the biosafety-literate criteria set at study start.
Long-term shedding and disseminated-infection surveillance as real-world use expands.
Named, credentialed, and on the record
Dr. Ashok Srivastava, MD, Ph.D., MBA
President & Chief Medical Officer
Board-certified oncologist and Board of Advisors member at Calidi Biotherapeutics, an oncolytic-virus and cell-therapy platform company — direct exposure to the biosafety and clinical judgment this modality demands, alongside 135 oncology & hematology trials across 20 countries.
Educate · Evaluate · Execute for OVT
Oncolytic virus safety briefing
Shedding monitoring, injection-site signal criteria, and IBC-readiness expectations — for your board and clinical team.
IHASG Readiness Assessment
A graded review of your safety governance against an OVT-specific standard, with a roadmap to Level 4.
Continuous Medical Oversight
A named physician reviewer on the Workbench, adjudicating viral-activity and shedding signals as they happen.
Questions OVT programs ask us
Is oncolytic virus safety review really different from standard immuno-oncology?
Yes — an oncolytic virus is a live biological agent. Viral shedding, injection-site reactions, and disseminated-infection risk are biosafety questions a generic immuno-oncology safety framework isn't built to catch.
Do you help with shedding-monitoring and household-contact protocols, not just infusion-site safety?
Yes — viral shedding monitoring, environmental precautions, and immunocompromised-contact guidance are part of the biosafety protocol we help design and review, not an afterthought to the clinical safety plan.
Is this specific to one oncolytic virus platform?
The live-biological-agent safety discipline applies across oncolytic virus platforms and delivery routes; the specific monitoring plan is scoped to your vector and administration route on a call.
Talk to an OVT safety expert.
Bring us the shedding-monitoring design, the biosafety protocol, or the safety review you're building.
Book a call